UPDATE 2-Merck to buy virus-based cancer drug firm Viralytics for $394 mln
February 21, 2018 at 08:14 AM EST
* "Tuck-in" deal broadens Merck's immuno-oncology line-up (Adds analyst comment, more on virus science)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.